The overall objective of this contract is to provide a resource for preclinical in vitro evaluation of new chemical substances against members of the respiratory virus group -- influenza type A, influenza type B, parainfluenza virus type 3, respiratory syncytial virus, measles, and adenovirus type 5. In the initial studies, experimental compounds will be screened using the CPE inhibition assay determined both by microscopic observation and by colorimetric changes following neutral red uptake. Initial cytotoxicity will be determined by visual inspection of treated cells and by the neutral red assay. Substances that have a selectivity index of ten or greater will be confirmed using the virus yield reduction assay. Cytotoxicity in confirming experiments will use viable cell count determined by Coulter counter. These confirmatory tests are designed to select substances that have potential for further evaluation in animal models and clinical trials. Further testing of active substances will be performed to determine the level of cell toxicity (i.e., DNA, RNA, and protein synthesis inhibition) and the mechanism of action (i.e., time of drug addition, metabolite challenge). When results warrant, additional studies such as testing the substances in combination with other compounds for toxicity and antiviral efficacy, and virucidal studies.

Project Start
1993-09-30
Project End
1998-09-29
Budget Start
1997-09-24
Budget End
1998-09-29
Support Year
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Utah State University
Department
Veterinary Sciences
Type
Schools of Earth Sciences/Natur
DUNS #
City
Logan
State
UT
Country
United States
Zip Code
84322
Mangel, W F; Brown, M T; Baniecki, M L et al. (2001) Prevention of viral drug resistance by novel combination therapy. Curr Opin Investig Drugs 2:613-6
Mangel, W F; McGrath, W J; Brown, M T et al. (2001) A new form of antiviral combination therapy predicted to prevent resistance from arising, and a model system to test it. Curr Med Chem 8:933-9
Barnard, D L; Sidwell, R W; Xiao, W et al. (1999) 2-5A-DNA conjugate inhibition of respiratory syncytial virus replication: effects of oligonucleotide structure modifications and RNA target site selection. Antiviral Res 41:119-34
Lin, Y M; Flavin, M T; Schure, R et al. (1999) Antiviral activities of biflavonoids. Planta Med 65:120-5
Player, M R; Barnard, D L; Torrence, P F (1998) Potent inhibition of respiratory syncytial virus replication using a 2-5A-antisense chimera targeted to signals within the virus genomic RNA. Proc Natl Acad Sci U S A 95:8874-9
Sidwell, R W; Huffman, J H; Barnard, D L et al. (1998) Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor. Antiviral Res 37:107-20
Tai, C Y; Escarpe, P A; Sidwell, R W et al. (1998) Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071. Antimicrob Agents Chemother 42:3234-41
Mendel, D B; Tai, C Y; Escarpe, P A et al. (1998) Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection. Antimicrob Agents Chemother 42:640-6
Barnard, D L; Hill, C L; Gage, T et al. (1997) Potent inhibition of respiratory syncytial virus by polyoxometalates of several structural classes. Antiviral Res 34:27-37